SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

被引：0
|
作者：
Forsythe, A. [1 ]
Arondekar, B. [2 ]
Tremblay, G. [1 ]
Chan, G. [2 ]
Su, Y. [3 ]
机构：
[1] Purple Squirrel Econ, New York, NY USA
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.103
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN21
引用
收藏
页码：A415 / A415
页数：1
相关论文
共 50 条
  • [21] A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial
    Dennis, Michael
    Hills, Robert K.
    Thomas, Ian
    Gupta, Sunil
    Panoskaltsis, Nicki
    Copland, Mhairi
    Burnett, Alan K.
    Russell, Nigel H.
    BLOOD, 2016, 128 (22)
  • [22] Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
    Yamauchi, Takahiro
    Yoshida, Chikashi
    Usuki, Kensuke
    Takada, Satoru
    Matsumura, Itaru
    Dobashi, Nobuaki
    Miyazaki, Yasushi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Asou, Norio
    Kuroda, Junya
    Ichikawa, Satoshi
    Komatsu, Norio
    Mendes, Wellington
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Jiang, Qi
    Wei, Andrew
    Ishizawa, Kenichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (09) : 1372 - 1382
  • [23] A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
    Karanes, C
    Kopecky, KJ
    Head, DR
    Grever, MR
    Hynes, HE
    Kraut, EH
    Vial, RH
    Lichtin, A
    Nand, S
    Samlowski, WE
    Appelbaum, FR
    LEUKEMIA RESEARCH, 1999, 23 (09) : 787 - 794
  • [24] CHEMOTHERAPY FOR ACUTE NONLYMPHOCYTIC LEUKEMIA WITH LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C)
    LIN, SF
    LIU, HW
    CHEN, TP
    ACTA HAEMATOLOGICA JAPONICA, 1990, 53 (01): : 45 - 50
  • [25] Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review
    Heuser, Michael
    Fernandez, Cedric
    Hauch, Ole
    Klibanov, Olga M.
    Chaudhary, Tanushree
    Rives, Vincent
    FUTURE ONCOLOGY, 2023, 19 (11) : 789 - 810
  • [26] EVALUATING DIFFERENT INDIRECT TREATMENT COMPARISON APPROACHES: A CASE STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE TO RECEIVE INTENSIVE CHEMOTHERAPY
    Tremblay, G.
    Westley, T.
    Arondekar, B.
    Cappelleri, J.
    Chan, G.
    Forsythe, A.
    Briggs, A.
    VALUE IN HEALTH, 2018, 21 : S17 - S17
  • [27] Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia
    Brunnberg, Uta
    Mohr, Michael
    Noppeney, Richard
    Duerk, Heinz A.
    Sauerland, Maria Cristina
    Mueller-Tidow, Carsten
    Krug, Utz O.
    Koschmieder, Steffen
    Kessler, Torsten
    Mesters, Rolf M.
    Schulz, Christiane
    Buchner, Thomas
    Ehninger, Gerhard
    Duehrsen, Ulrich
    Serve, Hubert
    Berdel, Wolfgang E.
    BLOOD, 2010, 116 (21) : 152 - 152
  • [28] Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy
    Sang-Bo Oh
    Sung-Woo Park
    Joo-Seop Chung
    Won-Sik Lee
    Ho-Seop Lee
    Su-Hee Cho
    Yoon-Suk Choi
    Sung-Nam Lim
    Ho-Jin Shin
    Annals of Hematology, 2017, 96 : 1801 - 1809
  • [29] LOW-DOSE ARA-C THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA IN ELDERLY PATIENTS
    POWELL, BL
    CAPIZZI, RL
    MUSS, HB
    BEARDEN, JD
    LYERLY, ES
    ROSENBAUM, DL
    MORGAN, TM
    RICHARDS, F
    JACKSON, DV
    WHITE, DR
    NELSON, EC
    BUTLER, WM
    ZEKAN, PJ
    CRUZ, JM
    COOPER, MR
    BUSS, DH
    SPURR, CL
    LEUKEMIA, 1989, 3 (01) : 23 - 28
  • [30] Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy
    Oh, Sang-Bo
    Park, Sung-Woo
    Chung, Joo-Seop
    Lee, Won-Sik
    Lee, Ho-Seop
    Cho, Su-Hee
    Choi, Yoon-Suk
    Lim, Sung-Nam
    Shin, Ho-Jin
    ANNALS OF HEMATOLOGY, 2017, 96 (11) : 1801 - 1809
12345